563 related articles for article (PubMed ID: 30093411)
1. Ectopic fibroblast growth factor receptor 1 promotes inflammation by promoting nuclear factor-κB signaling in prostate cancer cells.
Wang C; Ke Y; Liu S; Pan S; Liu Z; Zhang H; Fan Z; Zhou C; Liu J; Wang F
J Biol Chem; 2018 Sep; 293(38):14839-14849. PubMed ID: 30093411
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
3. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model.
Shukla S; Maclennan GT; Marengo SR; Resnick MI; Gupta S
Prostate; 2005 Aug; 64(3):224-39. PubMed ID: 15712212
[TBL] [Abstract][Full Text] [Related]
4. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.
Guasch G; Ollendorff V; Borg JP; Birnbaum D; Pébusque MJ
Mol Cell Biol; 2001 Dec; 21(23):8129-42. PubMed ID: 11689702
[TBL] [Abstract][Full Text] [Related]
5. Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-κB-induced inflammatory mediators production in RAW 264.7 cells.
Endale M; Park SC; Kim S; Kim SH; Yang Y; Cho JY; Rhee MH
Immunobiology; 2013 Dec; 218(12):1452-67. PubMed ID: 23735482
[TBL] [Abstract][Full Text] [Related]
6. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation.
Freeman KW; Gangula RD; Welm BE; Ozen M; Foster BA; Rosen JM; Ittmann M; Greenberg NM; Spencer DM
Cancer Res; 2003 Oct; 63(19):6237-43. PubMed ID: 14559809
[TBL] [Abstract][Full Text] [Related]
7. Signaling by FGF Receptor 2, Not FGF Receptor 1, Regulates Myelin Thickness through Activation of ERK1/2-MAPK, Which Promotes mTORC1 Activity in an Akt-Independent Manner.
Furusho M; Ishii A; Bansal R
J Neurosci; 2017 Mar; 37(11):2931-2946. PubMed ID: 28193689
[TBL] [Abstract][Full Text] [Related]
8. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk of FGFR1 signaling and choline metabolism promotes cell proliferation and survival in prostate cancer cells.
Fan Z; Ma J; Pan X; Zhao L; Wu Y; Lin H; Zhao Y; Jiang H; Pan T; Li X; Wang F; Wang C
Int J Cancer; 2022 May; 150(9):1525-1536. PubMed ID: 34985768
[TBL] [Abstract][Full Text] [Related]
10. Role of Src signal transduction pathways in scatter factor-mediated cellular protection.
Fan S; Meng Q; Laterra JJ; Rosen EM
J Biol Chem; 2009 Mar; 284(12):7561-77. PubMed ID: 19047046
[TBL] [Abstract][Full Text] [Related]
11. Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78.
Misra UK; Deedwania R; Pizzo SV
J Biol Chem; 2006 May; 281(19):13694-13707. PubMed ID: 16543232
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
13. FGF20-FGFR1 signaling through MAPK and PI3K controls sensory progenitor differentiation in the organ of Corti.
Su Y; Yang LM; Ornitz DM
Dev Dyn; 2021 Feb; 250(2):134-144. PubMed ID: 32735383
[TBL] [Abstract][Full Text] [Related]
14. Complex Systems Biology Approach in Connecting PI3K-Akt and NF-κB Pathways in Prostate Cancer.
Shankar E; Weis MC; Avva J; Shukla S; Shukla M; Sreenath SN; Gupta S
Cells; 2019 Feb; 8(3):. PubMed ID: 30813597
[TBL] [Abstract][Full Text] [Related]
15. The intracellular microenvironment in host cell-specific phosphorylation of SNT1 by the FGFR1 tyrosine kinase.
Jin CL; McKeehan K; Lambert D; Wang F
Shi Yan Sheng Wu Xue Bao; 2002 Sep; 35(3):184-90. PubMed ID: 15344379
[TBL] [Abstract][Full Text] [Related]
16. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells.
Huang F; Kao CY; Wachi S; Thai P; Ryu J; Wu R
J Immunol; 2007 Nov; 179(10):6504-13. PubMed ID: 17982039
[TBL] [Abstract][Full Text] [Related]
17. Lysophosphatidic acid activates the RhoA and NF-κB through Akt/IκBα signaling and promotes prostate cancer invasion and progression by enhancing functional invadopodia formation.
Hwang YS; Lee J; Zhang X; Lindholm PF
Tumour Biol; 2016 May; 37(5):6775-85. PubMed ID: 26662305
[TBL] [Abstract][Full Text] [Related]
18. Basic fibroblast growth factor-induced neuronal differentiation of mouse bone marrow stromal cells requires FGFR-1, MAPK/ERK, and transcription factor AP-1.
Yang H; Xia Y; Lu SQ; Soong TW; Feng ZW
J Biol Chem; 2008 Feb; 283(9):5287-95. PubMed ID: 18171671
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotection by transforming growth factor-beta1 involves activation of nuclear factor-kappaB through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein kinase-extracellular-signal regulated kinase1,2 signaling pathways.
Zhu Y; Culmsee C; Klumpp S; Krieglstein J
Neuroscience; 2004; 123(4):897-906. PubMed ID: 14751283
[TBL] [Abstract][Full Text] [Related]
20. NCAM- and FGF-2-mediated FGFR1 signaling in the tumor microenvironment of esophageal cancer regulates the survival and migration of tumor-associated macrophages and cancer cells.
Takase N; Koma Y; Urakawa N; Nishio M; Arai N; Akiyama H; Shigeoka M; Kakeji Y; Yokozaki H
Cancer Lett; 2016 Sep; 380(1):47-58. PubMed ID: 27317650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
